Active Ingredient History
Monofluorophosphate (MFP) is an anion, which is a phosphate group with one oxygen atom substituted with a fluorine atom. Sodium Monofluorophosphate is intended to be used by both petitioners in food supplements as a source of fluoride in the forms of multi-vitamin, multi-mineral supplements, solid tablets or tablets dispersible in liquid. The toxic effects of Monofluorophosphate are attributable to the fluoride ion released by the in vivo hydrolysis of the parent compound. The Monofluorophosphate ion appears to play no role. The acute toxicity of Monofluorophosphate is somewhat less than that of NaF, due to the lesser availability of fluoride in the short term from Monofluorophosphate. In the long term, Monofluorophosphate produces virtually the same picture of renal effects and skeletal storage of fluoride as does NaF. Sodium Monofluorophosphate dissociates into sodium and Monofluorophosphate ions in the intestinal tract, the latter being absorbed mainly in the upper small intestine. NCATS
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Dental Caries (approved 1996)
Compliance (Phase 4)
Dental Caries (Phase 3)
Dental Plaque (Phase 3)
Dentin Sensitivity (Phase 3)
Gingivitis (Phase 4)
Gonorrhea (Phase 2)
Head and Neck Neoplasms (Phase 4)
Hypersensitivity (Phase 2)
Stomatitis (Phase 3)
Tooth Erosion (Phase 2)
Urinary Bladder, Overactive (Phase 4)
Xerostomia (Phase 4)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
